Search Result

Results for "

CK2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) Adenosine Kinase (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (12) Autophagy (10) c-Kit (1) Casein Kinase (57) CDK (5) Checkpoint Kinase (Chk) (1) DAPK (1) DNA-PK (4) DYRK (2) EGFR (2) Endogenous Metabolite (2) Epigenetic Reader Domain (1) ERK (1) HDAC (2) HSP (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (1) Parasite (1) PI3K (5) Pim (4) Ras (2) Reactive Oxygen Species (ROS) (2) Reference Standards (4) SARS-CoV (4) SHP2 (2) SRPK (1) Topoisomerase (1) Trk Receptor (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (60) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (6) Neurological Disease (2)

By Targets:

11β-HSD (3)

Adenosine Kinase (2)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (12)

Autophagy (10)

c-Kit (1)

Casein Kinase (57)

CDK (5)

Checkpoint Kinase (Chk) (1)

DAPK (1)

DNA-PK (4)

DYRK (2)

EGFR (2)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

ERK (1)

HDAC (2)

HSP (1)

Isotope-Labeled Compounds (2)

Microtubule/Tubulin (1)

Parasite (1)

PI3K (5)

Pim (4)

Ras (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (4)

SARS-CoV (4)

SHP2 (2)

SRPK (1)

Topoisomerase (1)

Trk Receptor (1)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (60)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (6)

Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15535

DMAT 5+ Cited Publications CK2 Inhibitor; Casein kinase II Inhibitor	Casein Kinase	Cancer
DMAT is a potent and specific *CK2* inhibitor with an IC₅₀ value of 130 nM.

HY-132175

CK2 inhibitor 2	Casein Kinase	Cancer
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of *CK2, with an IC₅₀* of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC₅₀=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .

HY-158369

CK2-IN-10	Casein Kinase	Cancer
CK2-IN-10 (31), an allosteric *CK2* inhibitor, can be used in the research of cancer .

HY-169629

CK2 inhibitor 4	Casein Kinase	Cancer
CK2 inhibitor 4 (compound 5b) is a protein kinase CK2 inhibitor with IC₅₀ of 3.8 μM. CK2 inhibitor 4 can be used in tumor research .

HY-143461

CK2 inhibitor 3	Casein Kinase	Cancer
CK2 inhibitor 3 is a potent *CK2* inhibitor with IC₅₀ value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases .

HY-155987

CK2-IN-8	Casein Kinase	Cancer
CK2-IN-8 (compound 5c) is a *CK2* inhibitor with IC₅₀ >33 μM .

HY-12570

CK2-IN-9	Casein Kinase Wnt	Cancer
CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC₅₀ of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC₅₀ of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat .

HY-153788

CK2-IN-7	Casein Kinase	Cancer
CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer .

HY-121792

CK2-IN-1	Casein Kinase	Others
CK2-IN-1 is a *CK2* inhibitor, with an IC₅₀ of 150 nM .

HY-169985

CK2-IN-13	Casein Kinase	Cancer
CK2-IN-13 (compound 12c) is a potent inhibitor of *CK2, with the IC₅₀* of 5.8 nM. CK2-IN-13 plays an important role in cancer research .

HY-151382

CK2-IN-3	Casein Kinase	Cancer
CK2-IN-3 is a selective and potent *CK2* inhibitor (K_d: 12 nM), with IC₅₀ values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers .

HY-118403

CK2-IN-12	Casein Kinase	Infection Inflammation/Immunology Cancer
CK2-IN-12 (Compound 39) is an inhibitor for protein kinase CK2 with an IC₅₀ of 0.8 μM .

HY-168517

PIM-1/CK2-IN-2	Pim Casein Kinase Apoptosis	Cancer
PIM-1/CK2-IN-2 (compound 3aA) is a *PIM-1/CK2* inhibitor. PIM-1/CK2-IN-2 can induce the mitochondrial apoptotic pathway in CCRF-CEM cells. PIM-1/CK2-IN-2 can be used in cancer research .

HY-148328

CK2-IN-4	Casein Kinase	Infection Inflammation/Immunology Cancer
CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC₅₀=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis .

HY-158370

CK2-IN-11	Casein Kinase	Cancer
CK2-IN-11 (32) is an allosteric *CK2* inhibitor, with high selectivity for CK2 with IC₅₀ values of 19.3 nM and 15.6 nM for the CK2α2β2 and the CK2α′2β2 isoforms, respectively .

HY-14394

TBB 10+ Cited Publications NSC 231634; Casein Kinase II Inhibitor I	Casein Kinase	Cancer
TBB is a cell-permeable and ATP-competitive *CK2* inhibitor with an IC₅₀ of 0.15 μM for rat liver CK2.

HY-145260

BRD4/CK2-IN-1	Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy	Cancer
BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of *BRD4/CK2* (bromodomain-containing protein 4/casein kinase 2), with IC₅₀s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)

HY-135816

CK2/PIM1-IN-1	Casein Kinase Pim	Inflammation/Immunology Cancer
CK2/PIM1-IN-1 is an inhibitor of *CK2* and PIM1, with IC₅₀s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .

HY-174350

CK2-IN-15	Casein Kinase SARS-CoV	Infection
CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase *CK2* inhibitor with an IC₅₀ value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .

HY-148763

CK2-IN-6	Casein Kinase	Inflammation/Immunology Cancer
CK2-IN-6 is a potent protein kinase *CK2* inhibitor that can be used in the study of cancer as well as other kinase-related conditions, including inflammation, pain and certain immune diseases .

HY-103384

TMCB	Casein Kinase	Cancer
TMCB is a selective, ATP-competitive CK2 (casein kinase II) inhibitor with distinct K_i values of 83 nM and 21 nM for the two different catalytic CK2 subunits α and α', respectively .

HY-135906

CK2/ERK8-IN-1 2 Publications Verification	Casein Kinase ERK Pim DYRK Apoptosis	Cancer
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (K_i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC₅₀s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with K_is of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .

HY-168707

CK2-IN-14	Casein Kinase	Cancer
CK2-IN-14 (Compound 10b) is an inhibitor for cyclin kinase 2α with an IC₅₀ of 36.7 nM. CK2-IN-14 inhibits the growth of cancer cell 786-O and U937 with GI₅₀ of 7.3 μM and 7.5 μM .

HY-110052

TBCA 1 Publications Verification	Casein Kinase	Cancer
TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC₅₀ of 110 nM and a K_i of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .

HY-108606

PI-828 1 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, *CK2, and CK2α2* in lipid kinase assay, respectively .

HY-15479

TTP 22 2 Publications Verification	Casein Kinase	Inflammation/Immunology Cancer
TTP 22 is a potent *CK2* inhibitor, with an IC₅₀ of 100 nM and a K_i of 40 nM.

HY-158371

HDAC/CK2-IN-1	HDAC Casein Kinase	Cancer
HDAC/CK2-IN-1 (compound 38) is a HDAC1 (IC₅₀ = 1.46 μM), HDAC6 (IC₅₀ = 0.66 μM), and *CK2* (IC₅₀ = 3.67 μM) inhibitor. HDAC/CK2-IN-1 exhibits promising antproliferative activity against Jurkat, MCF-7, HCT-116, and HL-60 cell lines .

HY-50855B

Silmitasertib sodium salt 45+ Cited Publications CX-4945 sodium salt	Casein Kinase Autophagy	Cancer
Silmitasertib sodium salt is an orally bioavailable, highly selective and potent *CK2* inhibitor, with IC₅₀ values of 1 nM against CK2α and CK2α'.

HY-50855

Silmitasertib 45+ Cited Publications CX-4945	Casein Kinase Autophagy	Cancer
Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent *CK2* inhibitor, with IC₅₀ values of 1 nM against CK2α and CK2α'.

HY-117332

IQA CGP-029482	Casein Kinase	Cancer
IQA (CGP-029482) is a potent and selective protein kinase CK2 inhibitor .

HY-B0183A

Ellagic acid (hydrate)	Casein Kinase	Cancer
Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive *CK2* inhibitor, with an IC₅₀ of 40 nM and a K_i of 20 nM .

HY-B0183

Ellagic acid 15+ Cited Publications	Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2	Neurological Disease Cancer
Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of *CK2* and SHP2, with an IC₅₀ of 40 nM and a K_i of 20 nM.

HY-W042648

4,5,6,7-Tetrabromo-1H-benzimidazole	Casein Kinase	Others
4,5,6,7-Tetrabromobenzimidazole is a selective and ATP competitive *CK2* (casein kinase 2) inhibitor .

HY-50855BR

Silmitasertib sodium salt (Standard)	Casein Kinase Autophagy	Cancer
Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt). This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.

HY-120267

TID43	Casein Kinase	Cardiovascular Disease
TID43 is a *CK2* inhibitor, with an IC₅₀ of 0.3 μM. TID43 can be used for anti-angiogenic research .

HY-176561

IOR-160	Casein Kinase HDAC	Cancer
IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC₅₀ = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC₅₀s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research .

HY-50855R

Silmitasertib (Standard)	Casein Kinase Autophagy	Cancer
Silmitasertib (Standard) is the analytical standard of Silmitasertib. This product is intended for research and analytical applications. Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.

HY-124833

Quinalizarin	Casein Kinase	Cancer
Quinalizarin is a potent, selective and cell-permeable protein kinase *CK2* inhibitor with an K_i of ~50 nM and an IC₅₀ of 110 nM. Quinalizarin can induce apoptosis of certain cancer cells .

HY-124321

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase *CK2* holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

HY-124321A

Metralindole	CDK	Cancer
Metralindole is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase *CK2* holoenzyme. Metralindole shows good potential as a non-small cell lung cancer inhibitor .

HY-B0183R

Ellagic acid (Standard)	Reference Standards Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2	Neurological Disease Cancer
Ellagic acid (Standard) is the analytical standard of Ellagic acid. This product is intended for research and analytical applications. Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.

HY-50733A

CX-5011	Casein Kinase Ras Apoptosis	Cancer
CX-5011 is a *CK2* inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death .

HY-15260

XL413 5 Publications Verification BMS-863233	CDK	Cancer
XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC₅₀ of 3.4 nM, and also shows potent effect with IC₅₀s of 215, 42 nM on CK2, PIM1, respectively, and an EC₅₀ of 118 nM on pMCM.

HY-B0183S

Ellagic acid-13C12	Isotope-Labeled Compounds	Others
Ellagic acid- ¹³C₁₂ is ¹³ C-labeled Ellagic acid (HY-B0183). Ellagic acid is a natural antioxidant and acts as a potent and ATP-competitive inhibitor of *CK2* and SHP2, with an IC₅₀ of 40 nM and a K_i of 20 nM .

HY-15260A

XL413 monohydrochloride 5 Publications Verification BMS-863233 monohydrochloride	CDK	Cancer
XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC₅₀ of 3.4 nM, and also shows potent effect with IC₅₀s of 215, 42 nM on CK2, PIM1, respectively, and an EC₅₀ of 118 nM on pMCM.

HY-162078

Antiproliferative agent-46	Casein Kinase	Cancer
Antiproliferative agent-46 (compound 5e) is an inhibitor of the casein kinase-2 enzyme (CK2) receptor. Antiproliferative agent-46 has a potent antiproliferative activity with an IC₅₀ value of 5.75 μM on the U87 cell line .

HY-114653

SRPIN803	Casein Kinase SRPK	Cancer
SRPIN803 is a potent *CK2* and SRPK1 dual inhibitor, with IC₅₀s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .

HY-156816

ON 108600	Casein Kinase DYRK	Cancer
ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC₅₀s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .

HY-10108A

LY294002 hydrochloride Maximum Cited Publications 912 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits *CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

HY-115519

(E/Z)-GO289 2 Publications Verification	Casein Kinase	Cancer
(E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC₅₀=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0183

Ellagic acid 15+ Cited Publications	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Microorganisms other families Phenols Polyphenols Disease Research Fields Cancer	Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2
Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of *CK2* and SHP2, with an IC₅₀ of 40 nM and a K_i of 20 nM.

HY-14393

Emodin Maximum Cited Publications 27 Publications Verification Frangula emodin	Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-14393R

Emodin (Standard) Maximum Cited Publications 27 Publications Verification Frangula emodin (Standard)	Quinones Structural Classification Rheum palmatum L. Classification of Application Fields Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	Reference Standards SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-B0183A

Ellagic acid (hydrate)	Classification of Application Fields Ziziphus jujuba Source classification Phenols Polyphenols Plants Rhamnaceae Disease Research Fields Cancer	Casein Kinase
Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive *CK2* inhibitor, with an IC₅₀ of 40 nM and a K_i of 20 nM .

HY-B0183R

Ellagic acid (Standard)	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants Endogenous metabolite	Reference Standards Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2
Ellagic acid (Standard) is the analytical standard of Ellagic acid. This product is intended for research and analytical applications. Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.

Cat. No.	Product Name	Chemical Structure

HY-B0183S

Ellagic acid-13C12
Ellagic acid- ¹³C₁₂ is ¹³ C-labeled Ellagic acid (HY-B0183). Ellagic acid is a natural antioxidant and acts as a potent and ATP-competitive inhibitor of *CK2* and SHP2, with an IC₅₀ of 40 nM and a K_i of 20 nM .

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks